Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.

[1]  R. Rappuoli,et al.  Probing the structure‐activity relationship of Escherichia coli LT‐A by site‐directed mutagenesis , 1994, Molecular microbiology.

[2]  R. Rappuoli,et al.  Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing , 1994, Infection and immunity.

[3]  G. Dougan.  1993 Colworth Prize Lecture. The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development. , 1994, Microbiology.

[4]  R. Rappuoli.  Toxin inactivation and antigen stabilization: two different uses of formaldehyde. , 1994, Vaccine.

[5]  G. Dougan,et al.  Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. , 1993, Vaccine.

[6]  G. Dougan,et al.  Circulating cellular immune response to oral immunization of humans with cholera toxin B-subunit. , 1993, Vaccine.

[7]  R. Shahin,et al.  Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection , 1992, Infection and immunity.

[8]  C. Czerkinsky,et al.  Cholera as a model for research on mucosal immunity and development of oral vaccines. , 1992 .

[9]  J. Mcghee,et al.  The mucosal immune system: from fundamental concepts to vaccine development. , 1992, Vaccine.

[10]  R. Rappuoli,et al.  Properties of the B oligomer of pertussis toxin , 1991, Infection and immunity.

[11]  G. Dougan,et al.  The early cellular and humoral immune response to primary and booster oral immunization with cholera toxin B subunit , 1991, European journal of immunology.

[12]  I. Charles,et al.  Intranasal immunization using the B subunit of the Escherichia coli heat‐labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen , 1991, Molecular microbiology.

[13]  L. Nencioni,et al.  Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment , 1991, Infection and immunity.

[14]  R. Rappuoli,et al.  Towards third-generation whooping cough vaccines. , 1991, Trends in biotechnology.

[15]  D. OʼHagan.  Novel nonreplicating antigen delivery systems , 1990 .

[16]  L. Nencioni,et al.  Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.

[17]  B. Finlay,et al.  Common themes in microbial pathogenicity , 1989, Microbiological reviews.

[18]  Adhocgroupforthestudyofpert.  PLACEBO-CONTROLLED TRIAL OF TWO ACELLULAR PERTUSSIS VACCINES IN SWEDEN?PROTECIVE EFFICACY AND ADVERSE EVENTS , 1988 .

[19]  G. Russell-Jones,et al.  Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding , 1988, The Journal of experimental medicine.

[20]  W. Strober.  Mucosal immunity and infections at mucosal surfaces , 1988 .

[21]  C. Elson,et al.  Ir gene control of the murine secretory IgA response to cholera toxin , 1987, European journal of immunology.

[22]  J. Holmgren,et al.  Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. , 1986, Immunology.

[23]  R. Rappuoli,et al.  Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Elson,et al.  Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. , 1984, Journal of immunology.

[25]  J. Bienenstock,et al.  A common mucosal immunologic system involving the bronchus, breast and bowel. , 1978, Advances in experimental medicine and biology.